William Blair Has Pessimistic Outlook of XENE Q3 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Equities research analysts at William Blair lowered their Q3 2025 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a research note issued to investors on Tuesday, August 12th. William Blair analyst M. Minter now anticipates that the biopharmaceutical company will post earnings per share of ($1.20) for the quarter, down from their prior forecast of ($1.07). William Blair has a “Outperform” rating on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. William Blair also issued estimates for Xenon Pharmaceuticals’ Q4 2025 earnings at ($1.22) EPS, FY2025 earnings at ($4.32) EPS, Q1 2026 earnings at ($0.96) EPS, Q2 2026 earnings at ($1.16) EPS, Q3 2026 earnings at ($1.20) EPS, Q4 2026 earnings at ($1.27) EPS and FY2026 earnings at ($4.59) EPS.

Several other research analysts have also commented on the company. Evercore ISI started coverage on Xenon Pharmaceuticals in a research report on Wednesday, May 14th. They set an “outperform” rating and a $55.00 price target on the stock. Wedbush lifted their price target on Xenon Pharmaceuticals from $42.00 to $43.00 and gave the stock an “outperform” rating in a research report on Tuesday. Royal Bank Of Canada dropped their target price on Xenon Pharmaceuticals from $57.00 to $55.00 and set an “outperform” rating on the stock in a report on Tuesday. Needham & Company LLC decreased their price target on Xenon Pharmaceuticals from $60.00 to $55.00 and set a “buy” rating for the company in a report on Tuesday, May 13th. Finally, Wall Street Zen lowered shares of Xenon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 21st. One investment analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Xenon Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.20.

Xenon Pharmaceuticals Stock Up 0.8%

XENE opened at $37.96 on Thursday. The firm has a market cap of $2.93 billion, a price-to-earnings ratio of -10.69 and a beta of 1.16. Xenon Pharmaceuticals has a 52 week low of $26.74 and a 52 week high of $46.00. The business’s 50 day moving average is $32.46 and its two-hundred day moving average is $34.07.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same period in the previous year, the firm posted ($0.75) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC acquired a new position in shares of Xenon Pharmaceuticals during the second quarter valued at $25,000. Caitong International Asset Management Co. Ltd acquired a new position in Xenon Pharmaceuticals during the first quarter worth about $30,000. Elevation Point Wealth Partners LLC acquired a new position in Xenon Pharmaceuticals during the second quarter worth about $32,000. GF Fund Management CO. LTD. acquired a new position in Xenon Pharmaceuticals during the fourth quarter worth about $63,000. Finally, Quarry LP acquired a new position in Xenon Pharmaceuticals during the fourth quarter worth about $78,000. 95.45% of the stock is currently owned by institutional investors.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.